Laparoscopic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (L-CRS/HIPEC) for perforated low-grade appendiceal mucinous neoplasm (LAMN II)
Name:
10.1245_s10434-019-07277-z.pdf
Size:
166.2Kb
Format:
PDF
Description:
Full text, Open Access article
Affiliation
The Christie NHS Foundation Trust, Colorectal and Peritoneal Oncology Centre, Manchester, UKIssue Date
2019
Metadata
Show full item recordAbstract
INTRODUCTION: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is an established treatment for pseudomyxoma peritonei resulting from a perforated low-grade appendiceal mucinous neoplasm (LAMN II). In patients with localized disease, a laparoscopic procedure (L-CRS/HIPEC) can be undertaken. METHODS: This video demonstrates L-CRS/HIPEC in a 66-year-old male who had previously undergone an appendicectomy for an LAMN II lesion. The preoperative computed tomography (CT) scan suggested disease localized to the right iliac fossa. However, laparoscopic assessment unexpectedly revealed disease in the pelvis and on the right hemidiaphragm and liver surface. RESULTS: A technique for treating the thin film of mucin in the pelvis and on the right hemidiaphragm is demonstrated. The liver is mobilized to facilitate ablation of mucin on the serosal surface of the right lobe. Tips and tricks for starting the omentectomy, dealing with the vascular pedicle, and completing the dissection in the left upper quadrant are shown. The Peritoneal Cancer Index (PCI) score was 5 (3 for the right upper quadrant, 1 for the pelvis, 1 for the small bowel), and the cytoreduction score was CC-1. The operative duration was 8.5 h, and length of hospital stay was 5 days. The patient returned to work after 6 weeks. DISCUSSION: L-CRS/HIPEC can be performed when patients are unexpectedly found to have disease, provided the appendiceal pathology is low grade and the PCI score is low. There are potential benefits to this approach, with a shorter length of hospital stay and faster functional recovery when compared with traditional open surgery.Citation
Parkin E, Selvasekar C, Wilson M, Renehan A, O'Dwyer S, Aziz O. Laparoscopic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (L-CRS/HIPEC) for perforated low-grade appendiceal mucinous neoplasm (LAMN II). Ann Surg Oncol. 2019.Journal
Annals of Surgical OncologyDOI
10.1245/s10434-019-07277-zPubMed ID
30989495Additional Links
https://dx.doi.org/10.1245/s10434-019-07277-zType
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1245/s10434-019-07277-z
Scopus Count
Collections
Related articles
- Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms.
- Authors: Abudeeb H, Selvasekar CR, O'Dwyer ST, Chakrabarty B, Malcolmson L, Renehan AG, Wilson MS, Aziz O
- Issue date: 2020 Dec
- Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
- Authors: Di Leo A, Corvasce A, Weindelmayer J, Mason EJ, Casella F, de Manzoni G
- Issue date: 2020 Dec
- Risk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique.
- Authors: Fish R, Selvasekar C, Crichton P, Wilson M, Fulford P, Renehan A, O'Dwyer S
- Issue date: 2014 Jan
- Management of an inguinal hernia in patients with pseudomyxoma peritonei.
- Authors: Sugarbaker PH
- Issue date: 2017 Jun
- Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
- Authors: Baumgartner JM, Tobin L, Heavey SF, Kelly KJ, Roeland EJ, Lowy AM
- Issue date: 2015 May